Myriad Genetics executives to speak at SOPHiA GENETICS event, spotlighting industry partnerships
Myriad Genetics' Chief Scientific Officer Dale Muzzey and Senior Vice President of Companion Diagnostics Lou Welebob are slated to speak at an upcoming SOPHiA GENETICS event. Their participation highlights Myriad Genetics' dedication to fostering collaboration within the diagnostics sector, emphasizing shared vision and trust as key for industry partnerships. This engagement follows Myriad's recent announcements on breakthroughs in precision oncology and plans to attend other healthcare conferences.
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Analysts
Analysts have given Myriad Genetics (NASDAQ:MYGN) an average "Hold" rating, with a consensus one-year price target of $6.40. This outlook comes despite the company missing recent earnings estimates and revenue forecasts. Notably, corporate insiders, including the Director and CEO, have recently increased their holdings in the stock, adding 152,007 shares in the past 90 days.
Stocks With 20% Upside: Dollar Tree, Myriad Genetics, Antero Resources Analysis - News and Statistics
This article analyzes three stocks—Dollar Tree (DLTR), Myriad Genetics (MYGN), and Antero Resources (AR)—which some Wall Street analysts suggest have over 20% upside potential. The author, however, expresses caution regarding such optimistic forecasts, noting potential conflicts of interest from analysts and highlighting specific concerns for each company. While Dollar Tree faces declining sales and limited growth, and Myriad Genetics shows slow revenue growth and negative returns on capital, Antero Resources is presented without additional cautionary details.
Jackie Tohn joins Myriad Genetics in campaign to expand hereditary cancer test awareness
Myriad Genetics has announced a partnership with actress Jackie Tohn to launch a campaign aimed at increasing awareness about hereditary cancer testing, specifically using MyRisk Hereditary Cancer Test. This collaboration seeks to educate the public on genetic risks and encourage proactive screening for early detection and prevention. Myriad Genetics is also expanding its industry engagement through participation in upcoming healthcare conferences and recently launched its FirstGene Multiple Prenatal Screen.
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Actress Jackie Tohn has partnered with Myriad Genetics to raise awareness for hereditary cancer testing after discovering she carries a BRCA1 gene variant. Following her father's cancer diagnosis and genetic testing, Tohn underwent a prophylactic double mastectomy and plans for an oophorectomy due to an 85% chance of developing breast cancer and 65% chance of developing ovarian cancer. Myriad Genetics' MyRisk Hereditary Cancer Test screens for 11 cancer types and provides personalized risk assessments, offering early surveillance and risk-reducing measures.
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing Awareness
Myriad Genetics has partnered with actress Jackie Tohn to raise awareness about hereditary cancer testing using its MyRisk® Hereditary Cancer Test. Tohn, who discovered she carried a BRCA1 gene variant after her father's cancer diagnosis, underwent preventive surgeries and emphasizes the importance of early detection and personalized health management. The MyRisk test evaluates genetic risks for 11 cancer types, aiming to empower individuals, especially those with family histories of cancer or of Ashkenazi Jewish ancestry, to discuss genetic testing with their healthcare providers.
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life
Actress Jackie Tohn partnered with Myriad Genetics to share her story about hereditary cancer testing after discovering she carried a BRCA1 gene variant. Following her father's cancer diagnosis and genetic testing, Tohn underwent a prophylactic double mastectomy and plans for an oophorectomy due to her high risk of developing breast and ovarian cancers. She advocates for proactive health management and emphasizes the importance of hereditary cancer screening, especially for individuals of Ashkenazi Jewish ancestry.
Insider Buying: Paul Bisaro Acquires Shares of Myriad Genetics Inc (MYGN)
Paul Bisaro, a Director at Myriad Genetics Inc (MYGN), recently purchased 7,500 shares of the company, increasing his total holdings to 97,441 shares. This transaction marks the third insider buy for MYGN in the past year, with no sells. The stock is currently trading at $3.69, which is significantly below its GuruFocus Value of $15.06, suggesting it might be a "Possible Value Trap."
Myriad Genetics director Paul Bisaro buys $27,637 in stock By Investing.com
Paul Bisaro, a director at Myriad Genetics (NASDAQ:MYGN), purchased 7,500 shares of the company's common stock for a total of $27,637 on May 14, 2026, increasing his direct holdings to 97,441 shares. This insider transaction follows Myriad Genetics reporting mixed financial results for Q1 2026, with an adjusted EPS loss greater than expected and revenue slightly below forecasts. Despite these shortfalls, the stock saw a minor increase in aftermarket trading, and investors are watching the company's future plans closely.
Paul Bisaro (NASDAQ: MYGN) adds 7,500 Myriad Genetics shares
Myriad Genetics director Paul Bisaro reported an open-market purchase of 7,500 shares of Common Stock at $3.685 per share, increasing his direct holdings to 97,441 shares. This transaction, detailed in a Form 4 filing, signifies a positive sentiment and increased equity stake in the company by a key insider. The purchase involved a net investment of $27,638.
Myriad Genetics director Paul Bisaro buys $27,637 in stock
Myriad Genetics director Paul Bisaro purchased 7,500 shares of the company's common stock for $27,637 on May 14, 2026, increasing his direct holdings to 97,441 shares. This comes after Myriad Genetics reported mixed first-quarter 2026 financial results, missing both adjusted EPS and revenue expectations, yet seeing a minor aftermarket stock increase. Investors are watching how the company will address these financial shortfalls.
Myriad Genetics Inc stock (US62855J1043): shares react to Q1 2025 results and updated 2025 guidance
Myriad Genetics Inc (MYGN) has released its Q1 2025 results and updated its full-year 2025 guidance, drawing investor attention to its diagnostics strategy and US market presence. The article details the company's core business model in molecular and genetic testing, its main revenue drivers in hereditary cancer, prenatal, and pharmacogenomic testing, and its competitive position within the rapidly evolving diagnostics industry. It highlights the importance of US healthcare trends, legislation, and reimbursement policies for the company's performance.
Myriad Genetics (MYGN) price target decreased by 11.49% to 6.35
This article reports that the price target for Myriad Genetics (MYGN) has been decreased by 11.49%, bringing it down to $6.35. The information is sourced from MSN.
Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop
Myriad Genetics faced a Q1 2026 earnings miss, reporting an EPS of -$0.09 against an estimated -$0.06, which impacted its stock performance. Shares fell 4.30% to $4.45 on July 25, 2025, and are currently trading at $4.21, down 31.5% year-to-date. The company specializes in molecular diagnostics, offering genetic testing services primarily for hereditary cancer risk assessment, and operates in a competitive but growing US genomics market.
State Street (MYGN) reports 4.42M Myriad shares, 4.7% stake
State Street Corporation has filed a Schedule 13G, disclosing beneficial ownership of 4,424,027 shares of Myriad Genetics Inc. (MYGN), representing a 4.7% stake as of March 31, 2026. This passive investment indicates State Street does not intend to influence management. The filing details shared voting power of 4,164,534 shares and shared dispositive power of 4,424,027 shares, held across various State Street advisory entities.
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Myriad Genetics's Q1 2026 earnings fell short of Wall Street estimates, with the company reporting a miss on revenue and adjusted EPS, though reconfirming its full-year revenue and EBITDA guidance. Management attributed the results to investments in new products and an expanded commercial team, alongside challenges in the prenatal business. Key analyst questions focused on the drivers for projected second-half revenue growth, sales team contributions, and confidence in prenatal volume recovery, especially with the new FirstGene product.
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock
Larry Robbins' Glenview Capital has maintained a significant stake in Myriad Genetics, Inc. (MYGN) since 2019, holding almost 4.6 million shares as of Q4 2025. Despite this, the molecular diagnostics company has struggled to achieve profitability, reporting a GAAP net loss of $34.1 million in Q1 2026, with revenue growth trailing the US market average. Analysts have lowered price targets due to competition and a lack of clear path to profit.
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock
Myriad Genetics Inc. (NASDAQ:MYGN) is highlighted as a stock liked by Larry Robbins, whose fund Glenview Capital has consistently held a position since 2019. Despite the fund's investment and the company's molecular diagnostics focus, Myriad Genetics has faced challenges, reporting a GAAP net loss in Q1 2026 and experiencing revenue growth trailing the US market average. Analysts have lowered price targets, and critics question its path to profitability given increasing competition.
Myriad Genetics in record sell-off after Q1 miss
This article reports on Myriad Genetics experiencing a record sell-off following a significant miss in its Q1 earnings report. The stock's poor performance indicates investor concern over the company's financial results.
Myriad Genetics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:MYGN) 2026-05-08
Myriad Genetics, Inc. (NASDAQ:MYGN) released its Q1 2026 earnings, reporting an EPS of -$0.09, missing estimates by $0.02, and revenue of $200.40M, a 2.30% year-over-year increase but missing estimates by $2.04M. The company published a slide deck in conjunction with its earnings call.
Myriad Genetics, Inc. (MYGN) Stock Analysis: Evaluating a Promising 77.94% Upside Potential
Myriad Genetics (MYGN) is a diagnostics and research company with a market cap of $386.29 million, operating in precision medicine. Despite a 20.80% revenue decline and negative financial metrics, analysts project a 77.94% upside potential, with an average target price of $7.28 from its current $4.09. The company's focus on innovation and collaborations, particularly in oncology, women's health, and pharmacogenomics, positions it as a complex but potentially rewarding long-term investment despite existing risks and volatility.
Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns
Myriad Genetics (MYGN) reported a Q1 2026 loss of US$34.1 million, with basic EPS at -US$0.36, highlighting ongoing profitability challenges. The company's revenue growth of 5.7% over the last 12 months trails the broader US market, and analysts do not forecast a return to profit within the next three years. Despite a low P/S ratio of 0.5x compared to peers, the market remains concerned about execution risks and the company's inability to achieve profitability given its recurring losses.
Myriad Genetics (Nasdaq:MYGN) - Stock Analysis
This article provides a detailed stock analysis of Myriad Genetics (MYGN), a molecular diagnostics and precision medicine company. It covers the company's financial performance, including revenue and earnings reports, analyst price targets, and recent news and updates regarding product development, clinical trials, and executive changes. The analysis highlights the company's current valuation, future growth prospects, and various diagnostic tests such as Precise MRD, MyRisk Hereditary Cancer Test, and GeneSight Psychotropic test.
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, Inc. announced its participation in two upcoming investor healthcare conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026, where a fireside chat will be webcast. The company is a leader in molecular diagnostic testing and precision medicine, aiming to improve patient care through genetic insights.
Myriad Genetics Is Maintained at Hold by TD Cowen
TD Cowen has maintained its Hold rating on Myriad Genetics (NASDAQ: MYGN). This indicates a neutral outlook by the firm on the company's stock performance.
Myriad Genetics to Present at Investor Healthcare Conferences
Myriad Genetics has announced its participation in upcoming investor healthcare conferences. The company plans to engage with investors and stakeholders, providing updates on its strategic initiatives and financial performance at these events. These conferences serve as a platform for healthcare companies to communicate with the investment community.
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, Inc. announced its management will participate in two upcoming investor healthcare conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The Goldman Sachs presentation will be available via live audio webcast on Myriad's investor relations website. Myriad Genetics focuses on molecular diagnostic testing and precision medicine, providing tests to uncover genetic insights, assess disease risk, and guide treatment decisions.
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics, Inc. announced its participation in two upcoming healthcare conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company's management will hold 1-to-1 investor meetings and a fireside chat, with the latter being available via live audio webcast. Myriad Genetics focuses on molecular diagnostic testing and precision medicine to advance health through genetic insights.
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2026 Earnings Call Transcript
Myriad Genetics (NASDAQ:MYGN) reported its Q1 2026 earnings, with reported EPS missing expectations at $-0.09 against an expected $-0.06. Despite this, the company reaffirmed its 2026 financial guidance, anticipating sequential revenue growth in Q2 and acceleration in the latter half of the year, driven by strong growth in hereditary cancer testing, solid GeneSight mental health test demand, and improvements in its prenatal business with the upcoming FirstGene launch. Management highlighted strategic investments in its Cancer Care Continuum, including expanded commercial capabilities and new product launches like Precise MRD and AI-enhanced Prolaris.
Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns
Myriad Genetics (MYGN) reported a Q1 2026 loss of US$34.1 million on revenues of US$200.4 million, with basic EPS loss at US$0.36. The company's profitability concerns persist, as losses have widened over the past five years and analysts do not foresee a return to profit within the next three years. Despite modest revenue growth of 5.7%, it lags the US market average, and the stock trades at a low 0.5x P/S ratio, reflecting market skepticism about its path to profitability.
Myriad Genetics stock in sell-off after Q1 miss (MYGN:NASDAQ)
Myriad Genetics (MYG) experienced a significant stock sell-off, losing approximately 20% in one day, after reporting Q1 2026 financials that missed Street forecasts. Despite the miss, the molecular diagnostics firm reaffirmed its outlook. The company reported $200.4M in revenue for the quarter.
Myriad Genetics (NASDAQ: MYGN) posts Q1 2026 loss amid higher costs and impairment
Myriad Genetics (NASDAQ: MYGN) reported a net loss of $34.1 million in Q1 2026, widening from near breakeven a year ago, despite a modest revenue increase to $200.4 million. The loss was primarily attributed to a $5.4 million goodwill and long-lived asset impairment charge and the absence of a prior one-time tax benefit. The company saw revenue growth in its Cancer Care Continuum and Mental Health segments, offset by a decline in Prenatal Health.
Myriad Genetics Q1 2026 Earnings Call Transcript
Myriad Genetics reported Q1 2026 revenue of $200.4 million, reaffirming its full-year 2026 guidance. The company saw strong growth in hereditary cancer testing and GeneSight, with hereditary cancer testing volume up 14% year-over-year and GeneSight revenue up 24% year-over-year. Myriad Genetics is also expanding its commercial team and preparing for key product launches including Precise MRD for breast cancer and AI-enhanced Prolaris for prostate cancer, while addressing a decline in prenatal revenue.
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Myriad Genetics reported first-quarter 2026 revenue of $200.4 million, a 2% year-over-year increase, and reaffirmed its full-year 2026 financial guidance. The company highlighted strong performance in its Cancer Care Continuum and Mental Health segments, partially offset by a decline in Prenatal Health. Key achievements include the launch of Precise Molecular Residual Disease (MRD) testing and FDA approval for the MyChoice CDx test.
Myriad Genetics Reports First Quarter 2026 Financial Results; Reiterates 2026 Financial Guidance Reflecting Ongoing Progress in the Cancer Care Continuum Business
Myriad Genetics reported strong first-quarter 2026 financial results, with revenue growing 2% year-over-year to $200.4 million, driven by growth in Cancer Care Continuum and Mental Health testing volumes. The company also announced the launch of Precise Molecular Residual Disease (MRD) and FDA approval for its MyChoice CDx test, while reaffirming its full-year 2026 financial guidance. Despite a decline in Prenatal Health volume, Myriad Genetics expresses confidence in continued growth from new tests and strategic initiatives.
Myriad Genetics (NASDAQ: MYGN) Q1 2026 revenue up 2% as loss widens
Myriad Genetics reported a 2% year-over-year revenue increase to $200.4 million in Q1 2026, driven by growth in Cancer Care Continuum and Mental Health segments, despite a decline in Prenatal Health. The company's GAAP net loss widened to $34.1 million, and it reported an adjusted loss per share of $0.09 and adjusted EBITDA of $(4.5) million. Myriad Genetics reiterated its full-year 2026 revenue guidance of $860–$880 million and adjusted EBITDA guidance of $37–$49 million, signaling expectations for improved profitability later in the year.
Myriad Genetics (NASDAQ: MYGN) CCO has shares withheld to cover RSU taxes
Myriad Genetics' (NASDAQ: MYGN) Chief Commercial Officer, Brian J. Donnelly, had 55,975 shares of common stock withheld to cover tax obligations related to the vesting of restricted stock units. The shares were withheld at a price of $4.80 per share, and Donnelly now directly holds 568,363 shares. This transaction is a routine administrative event for RSU tax withholding, not an open-market sale.
Myriad Genetics introduces FirstGene Multiple Prenatal Screen at ACOG2026 with interactive experience
Myriad Genetics is launching its FirstGene Multiple Prenatal Screen at the ACOG2026 conference, featuring an interactive Claw Machine Challenge to highlight the simplicity of their screening solution. This introduction follows previous unveils and the company's recognition on Forbes' 2026 America's Best Employers for Company Culture list, reinforcing their engagement with clinicians and industry professionals. Attendees can visit booth 331 to learn more and connect with the Myriad Genetics team.
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
A national survey by Myriad Genetics, Inc. (NASDAQ: MYGN) revealed that 88% of patients with depression and/or anxiety would feel more confident with a personalized mental health care plan. The survey, called the GeneSight Mental Health Monitor, highlighted that many patients feel current mental health treatment is "one-size-fits-all" and lacks personalization. It also showed low awareness about genetic testing tools, like the GeneSight Test, that could help inform medication decisions, despite a strong desire for individualized approaches among patients.
Myriad Genetics National Survey: 88% of Patients with Depression and/or Anxiety Would Feel More Confident with a Personalized Mental Health Care Plan
A national survey by Myriad Genetics, Inc. reveals that a significant majority of patients with depression and/or anxiety desire more personalized mental health care, with 88% indicating they would feel more confident if their treatment plan was tailored to them. Many find current treatments "one-size-fits-all" and are unaware that genetic testing, like the GeneSight Test, could help inform medication decisions. The findings highlight a strong patient preference for individualized approaches in mental health treatment, which often involves trial and error.
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Myriad Genetics, Inc. (NASDAQ: MYGN) announced it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after market close. Following the release, the company will host an earnings conference call at 4:30 pm ET to provide a financial overview and business update. A live webcast and archived replay will be available on Myriad's investor relations website.
Myriad Genetics (MYGN) to Release Quarterly Earnings on Tuesday
Myriad Genetics (NASDAQ: MYGN) is scheduled to release its Q1 2026 earnings on Tuesday, May 5th, with analysts forecasting a loss of ($0.07) per share and revenue of $202.39 million. Significant insider buying has been noted, with directors and the CEO acquiring substantial shares, bringing total insider ownership to 2.40%. Despite recent positive surprises in EPS and revenue, the company remains unprofitable with a negative net margin and ROE, leading to a consensus "Hold" rating and an average price target of $8.94.
Myriad Genetics Q3 2025 Earnings Preview
This article provides a preview of Myriad Genetics' upcoming Q3 2025 earnings report. It highlights expectations for the company's financial performance, including anticipated revenue and earnings per share, and discusses factors that could influence the results.
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Myriad Genetics, Inc. (NASDAQ: MYGN) announced it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after the market closes. The company will also host an earnings conference call at 4:30 pm ET on the same day to provide a financial overview and business update. A live webcast and archived recording will be available on Myriad's Investor Relations website.
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that it will release its first quarter 2026 financial results and hold an earnings conference call on Tuesday, May 5, 2026, after market close. The call will provide a financial overview and business update, with a live webcast available on the company's Investor Relations website.
Myriad Genetics to Release First Quarter 2026 Financial Results on May 5, 2026
Myriad Genetics, Inc. (NASDAQ: MYGN) announced that it will release its first quarter 2026 financial results on May 5, 2026, after the market closes. The company will also host an earnings conference call at 4:30 pm ET on the same day to provide a financial overview and business update. Investors can access a live webcast and registration details on Myriad's Investor Relations website.
After the bell on May 5, Myriad Genetics will post Q1 results
Myriad Genetics (NASDAQ: MYGN) is scheduled to release its first-quarter 2026 financial results on May 5, 2026, after market close, followed by a conference call and webcast at 4:30 p.m. ET. The company will provide a financial overview and business update during the call, accessible via its Investor Relations website where an archived webcast will also be available. This announcement follows recent developments, including FDA approval for its MyChoice CDx test and the commercial launch of the Precise MRD test, with investors keen to see updates on revenue growth, profitability, and execution of the "New Myriad" strategy.
Myriad Genetics Q3 2025 Earnings Preview
This article provides a preview of Myriad Genetics' upcoming Q3 2025 earnings report. It does not contain further details or predictions about the earnings.
Myriad Genetics unveils FirstGene Multiple Prenatal Screen at Washington D.C. symposium
Myriad Genetics is launching its FirstGene Multiple Prenatal Screen at a symposium in Washington, D.C. on May 3. This single-draw test is designed to simultaneously assess multiple genetic risks, offering a technologically advanced solution for comprehensive prenatal screening. The company, recently recognized by Forbes for its company culture, continues to expand its offerings in reproductive health and genetic risk assessment.
Myriad Genetics announces CFO appointment
The provided content is empty. Therefore, a summary cannot be generated.
